Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Next Science Ltd ( (AU:NXS) ).
Next Science Limited announced the results of its General Meeting, where the resolution proposed was passed by the required majority through a poll. This outcome aligns with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001. The successful passing of the resolution is a significant step for the company, potentially impacting its operational strategies and strengthening its position in the medical technology industry.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science is a medical technology company based in Sydney, Australia, with a research and development center in Florida, USA. Founded in 2012, the company focuses on developing and commercializing its proprietary XBIO™ technology, which effectively reduces biofilm-based infections in human health. The technology is unique, non-toxic, and has proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns all patent-protected intellectual property related to XBIO™.
Average Trading Volume: 558,373
Technical Sentiment Signal: Sell
Current Market Cap: A$42.43M
See more data about NXS stock on TipRanks’ Stock Analysis page.